Proto-oncogene tyrosine-protein kinase Src — Drug Target

All drugs that target Proto-oncogene tyrosine-protein kinase Src — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Adenosine Receptor Agonist · Alkylating Drug [EPC]

Marketed (2)

• Adenovite · Adenosine Receptor Agonist · Respiratory
• Yondelis · Janssen Prods · Alkylating Drug [EPC] · Oncology
  Yondelis works by binding to DNA and causing interstrand crosslinks, thereby inhibiting cancer cell growth.